Active substance
Pyrantel
- SFDA 1
- Health Canada 4
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| COMBANTRIN 250MG TAB | 250 mg | Tablet · Oral use | 6 Blister | SAR 5.80 | NCE · Prescription | PFIZER | Withdrawn by MAH · Not Marketed |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| COMBANTRIN TAB 125MG | 01944363 | 125 MG | TABLET · ORAL | KENVUE CANADA INC. |
| JAMP-PYRANTEL PAMOATE | 02380617 | 125 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP-PYRANTEL PAMOATE SUSPENSION | 02412470 | 50 MG / ML | SUSPENSION · ORAL | JAMP PHARMA CORPORATION |
| RIVA-PYRANTEL PAMOATE | 02535467 | 125 MG | TABLET · ORAL | LABORATOIRE RIVA INC. |
WHO WHO Model List of Essential Medicines (2025)
- 6.1.1. Intestinal anthelminthics · core
Hookworm diseases; Trichuriasis; Ascariasis; Enterobiasis
Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.